证券日报网讯 8月20日晚间，华润三九发布公告称，公司计划于2025年8月28日（星期四）15：00-16： 00联合公司控股子公司昆药集团股份有限公司、天士力医药集团股份有限公司举办2025年半年度业绩说 明会。 （编辑 任世碧） ...

证券日报网讯8月20日晚间，昆药集团（600422）发布公告称，公司计划于2025年8月28日15：00-16： 00联合公司控股股东华润三九（000999）医药股份有限公司、公司关联方天士力（600535）医药集团股 份有限公司举行2025年半年度网上业绩说明会。 ...

Group 1 - The company Tianjin Tasly Pharmaceutical Co., Ltd. announced plans to hold a semi-annual performance briefing on August 28, 2025, from 15:00 to 16:00 [2] - The briefing will be conducted in collaboration with its controlling shareholder, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., and its affiliate, Kunming Pharmaceutical Group Co., Ltd. [2]

证券代码：600535 证券简称：天士力 编号：临 2025-055 号 天士力医药集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2025 年 8 月 21 日（星期四）至 2025 年 8 月 25 日（星期一） 16:00 前访问全景投资者关系互动平台（http://ir.p5w.net/zj/）进入问题征集专题页 面，或通过公司邮箱 stock@tasly.com 进行提问。公司将在说明会上对投资者普遍 关注的问题进行回答。 天士力医药集团股份有限公司（以下简称"公司"）已于 2025 年 8 月 16 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年 度经营成果、财务状况，公司计划于 2025 年 8 月 28 日下午 15:00-16:00，联合公 司控股股东华润三九医药股份有限公司、公司关联方昆药集团股份有限公司举办 2025 年半年度业绩说明会，就投资者关心的问题进行交流 ...

Core Insights - Tianjin Tasly Pharmaceutical Group Co., Ltd. reported a total revenue of 4.288 billion yuan for the first half of 2025, a year-on-year decrease of 1.91% [1] - The company's net profit attributable to shareholders reached 775 million yuan, reflecting a year-on-year increase of 16.97% [1] - The company has a current ratio of 3.314 and a quick ratio of 2.683, indicating strong liquidity [1] Financial Performance - Total revenue for the first half of 2025: 4.288 billion yuan, down 1.91% year-on-year [1] - Net profit attributable to shareholders: 775 million yuan, up 16.97% year-on-year [1] - Non-recurring net profit: 640 million yuan, down 12.87% year-on-year [1] - Asset-liability ratio: 18.43% [1] Market Activity - As of August 19, 2025, the stock price closed at 17.38 yuan, with an increase of 1.94% [1] - Trading volume was 542,100 hands, with a transaction amount of 949.7 million yuan [1] - Main funds experienced a net outflow of 21.79 million yuan, accounting for 2.3% of the transaction amount [1] Company Overview - Tianjin Tasly Pharmaceutical Group was established in 1998 and is primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 14.9395 billion yuan [1] - The company has made investments in 39 enterprises and participated in 5,000 bidding projects [2]

Core Viewpoint - The company reported a slight decline in revenue for H1 2025, but a significant increase in net profit, indicating a mixed financial performance amidst strategic adjustments and ongoing integration with China Resources [1][2]. Financial Performance - For H1 2025, the company achieved revenue of 4.288 billion yuan, a year-on-year decrease of 1.91% [1]. - The net profit attributable to shareholders was 775 million yuan, reflecting a year-on-year increase of 16.97% [1]. - The non-recurring net profit was 640 million yuan, down 12.87% year-on-year [1]. - In Q2 2025, revenue was 2.233 billion yuan, a decline of 3.86% year-on-year, while net profit rose by 25.41% to 460 million yuan [1]. Industry Performance - The pharmaceutical industry maintained stability, with the company's pharmaceutical manufacturing segment generating revenue of 3.879 billion yuan, remaining flat year-on-year [2]. - The pharmaceutical commercial segment saw a revenue decline of 14.88%, totaling 386 million yuan [2]. - The company adjusted its product classification, now categorizing products by treatment area rather than type, aligning with future strategic goals [2]. Strategic Integration - The integration with China Resources is progressing smoothly, expected to bring positive changes [3]. - Following the acquisition completion on March 27, 2025, the company is implementing a "100-day integration" plan focusing on operational management, strategic planning, and channel expansion [4]. - The collaboration with China Resources' health consumer goods business aims to enhance strategic partnerships with leading retail pharmacies [4]. R&D Pipeline - The company is increasing its R&D efforts, focusing on cardiovascular, neurological, and digestive health, with 83 projects in the pipeline, including 31 innovative drugs [5][6]. - Seven clinical research projects were initiated in H1 2025, with 29 projects currently in clinical trials, including 21 in phases II and III [6]. - The company is advancing modern traditional Chinese medicine and focusing on biopharmaceuticals, having received clinical approvals for several innovative products [6]. Profit Forecast - Revenue projections for 2025-2027 are 8.660 billion yuan, 9.324 billion yuan, and 10.081 billion yuan, respectively [7]. - Expected net profits for the same period are 1.196 billion yuan, 1.331 billion yuan, and 1.484 billion yuan, with corresponding diluted EPS of 0.80 yuan, 0.89 yuan, and 0.99 yuan [7].

Group 1 - The pharmaceutical industry remains stable, with a reclassification of product categories [2] - The integration with China Resources is progressing smoothly, which is expected to bring positive changes [2] - The research and development pipeline is rich, indicating a potential for value reassessment [2]

Investment Rating - The report assigns a "Buy" rating for the company, indicating that the stock price is expected to outperform the benchmark index by more than 15% [12]. Core Views - The integration with China Resources is progressing smoothly, which is expected to bring positive changes to the company [3]. - The company has a rich pipeline of research and development projects, which may lead to a revaluation of its value [4]. Financial Performance Summary - In H1 2025, the company achieved operating revenue of 4.288 billion, a year-on-year decrease of 1.91%, while the net profit attributable to the parent company was 775 million, a year-on-year increase of 16.97% [1]. - The company’s pharmaceutical industry revenue was 3.879 billion, remaining stable year-on-year, while the pharmaceutical commercial revenue decreased by 14.88% [2]. - The company’s net profit and non-recurring net profit showed significant differences due to fair value changes, which were 77 million in H1 2025 compared to -88 million in H1 2024 [2]. Strategic Developments - The company has restructured its product classification to align with its future development strategy, categorizing products by therapeutic areas rather than by type of medicine [2]. - The company is actively implementing the management philosophy of China Resources, enhancing operational efficiency and management systems [3]. - The company is collaborating with China Resources' health consumer goods business to deepen strategic partnerships with leading retail pharmacies [3]. R&D Pipeline - The company has increased its R&D efforts, focusing on three core areas: cardiovascular and metabolism, neurology/psychiatry, and digestion, with 83 projects in the pipeline, including 31 innovative drugs [4]. - The company has received clinical approval for three products, including the world's first mesenchymal stem cell injection approved for IND in the U.S. [4]. - The report highlights that the market has not fully priced the company's innovative biopharmaceutical developments, indicating potential for value revaluation [4]. Earnings Forecast - The company is expected to achieve operating revenues of 8.66 billion, 9.32 billion, and 10.08 billion for the years 2025, 2026, and 2027, respectively [6]. - The net profit attributable to the parent company is projected to be 1.196 billion, 1.331 billion, and 1.484 billion for the same years [6]. - The report anticipates an increase in EPS (diluted) to 0.80, 0.89, and 0.99 for 2025, 2026, and 2027, respectively [6].

Overall Research - The domestic equity market continues to rise, with the ChiNext Index increasing by 8.58%. The performance of equity and bond funds is diverging, with equity mixed funds leading the gains. TMT theme funds are significantly outperforming, while consumer themes show relatively weaker growth. Passive index funds in financial and AI themes are performing well, while there is a net outflow from domestic stock ETFs, particularly in the double innovation sector and TMT themes, with noticeable inflows into large-cap and broad-based funds [1]. Real Estate Industry - As of August 17, 2025, new home transactions in 20 cities totaled 491,000 units, down 5.5%. In major cities, Beijing saw 26,000 units sold (-13%), Shanghai 63,000 units (-1%), and Shenzhen 19,000 units (-3%). In the second-hand housing market, transactions in 10 cities reached 490,000 units, up 10.7%, with Beijing at 108,000 units (+11%), Shanghai 160,000 units (+18%), and Shenzhen 44,000 units (+28%) [2]. Metal Industry - The growth rate difference between M1 and M2 narrowed to -3.2 percentage points in July, marking a near 49-month high. The steel sector's profitability is expected to recover to historical average levels following the Ministry of Industry and Information Technology's guidelines for the steel industry. However, there are risks associated with significant fluctuations in futures prices due to trading restrictions on coking coal futures [3]. Chemical Industry - The report suggests focusing on companies involved in electronic specialty gases, such as nitrogen trifluoride and other products. Key companies include China Shipbuilding Industry Corporation, Nanda Optoelectronics, and Huate Gas. Additionally, companies producing semiconductor materials, such as photolithography resins and PCB inks, are also recommended for attention [4]. Company Research - Sinopec Engineering achieved a revenue of 31.6 billion yuan in H1 2025, a 10.1% year-on-year increase, with a net profit of 1.384 billion yuan, up 4.8%. The company maintains a "buy" rating with profit forecasts for 2025-2027 at 2.595 billion, 2.760 billion, and 2.902 billion yuan, respectively [7]. - Blue Sky Technology won a new lithium extraction project, with expectations for high growth in its lithium resource business. The company forecasts net profits of 1.055 billion, 1.253 billion, and 1.495 billion yuan for 2025-2027, maintaining an "increase" rating [8]. - Changqing Co. reported a recovery in pesticide market demand, with a net profit forecast of 74 million, 128 million, and 181 million yuan for 2025-2027, maintaining an "increase" rating despite a downward adjustment in profit expectations [9]. - Huayou Cobalt's net profit for H1 2025 reached 2.71 billion yuan, a 62.3% increase year-on-year, with future profit forecasts of 5.9 billion, 7.1 billion, and 8.6 billion yuan for 2025-2027, maintaining a "buy" rating [10]. - Keda Li's main business remains stable, with profit forecasts of 1.802 billion, 2.178 billion, and 2.499 billion yuan for 2025-2027, maintaining a "buy" rating [11]. - Oriental Cable's revenue for H1 2025 was 4.432 billion yuan, an 8.95% increase, but net profit fell by 26.57% to 473 million yuan. The company expects growth in the second half of 2025 due to increased cable deliveries [12]. - Jinlang Technology reported a revenue of 3.794 billion yuan in H1 2025, a 13.09% increase, with a net profit of 602 million yuan, up 70.96%. Future profit forecasts are 1.169 billion, 1.399 billion, and 1.657 billion yuan for 2025-2027, maintaining an "increase" rating [12]. - Lian Microelectronics has seen a recovery in its epitaxial wafer business, with future profit forecasts of 69 million, 165 million, and 242 million yuan for 2025-2027, maintaining a "buy" rating [13]. - Tian Shili achieved a revenue of 4.288 billion yuan in H1 2025, with a net profit of 775 million yuan, up 16.97%. The company maintains profit forecasts of 1.150 billion, 1.245 billion, and 1.399 billion yuan for 2025-2027, maintaining a "buy" rating [14]. - Ecovacs Robotics reported strong performance in both domestic and international sales, with profit forecasts of 1.6 billion, 1.9 billion, and 2.3 billion yuan for 2025-2027, maintaining a "buy" rating [15]. - Stone Technology, a leader in smart vacuum robots, has adjusted its profit forecasts to 1.7 billion, 2.1 billion, and 2.5 billion yuan for 2025-2027, maintaining an "increase" rating [16].

Group 1 - The company Tianjin Tianshi Biological Pharmaceutical Co., Ltd. has applied for a "Type III meeting" with the CDE, currently in "processing" status [1] - Type III meetings are held to discuss significant issues at critical stages and are typically scheduled within 75 days after the application [1] - Tianjin Tianshi Biological Pharmaceutical Co., Ltd. was established in 2001 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 10.8257 billion RMB and paid-in capital of 10 billion RMB [1] Group 2 - The company has made investments in three enterprises and participated in 225 bidding projects [1] - In terms of intellectual property, the company holds 2 trademark registrations and 73 patents, along with 156 administrative licenses [1] - The major shareholders of the company include Tianjin Tianshi Pharmaceutical Group Co., Ltd. holding 95% and Tianjin Tianshi Enterprise Management Co., Ltd. holding 5% [1]